Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226433 | 1.00 | ABCG2 (0.58) | ABCG2NFE2L2ALDH1A1HDAC3TNKS | |
| SCHEMBL1168385 | 0.87 | SMN1; SMN2 (0.65) | ALDH1A1HPGDSMN1; SMN2LMNAALOX12 | |
| SCHEMBL23778879 | 0.87 | MAOB (0.61) | ABCG2NFE2L2ALDH1A1HDAC3TNKS | |
| SCHEMBL29935336 | 0.87 | SMN1; SMN2 (0.65) | ALDH1A1HPGDSMN1; SMN2LMNAALOX12 | |
| SCHEMBL1168384 | 0.87 | SMN1; SMN2 (0.65) | ALDH1A1HPGDSMN1; SMN2LMNAALOX12 | |
| SCHEMBL1399070 | 0.86 | ABCG2 (0.49) | ABCG2NFE2L2ALDH1A1HDAC3TNKS | |
| SCHEMBL1399072 | 0.86 | ABCG2 (0.49) | ABCG2NFE2L2ALDH1A1HDAC3TNKS | |
| SCHEMBL3574506 | 0.84 | ABCG2 (0.59) | ABCG2NFE2L2ALDH1A1KRASHPGD | |
| SCHEMBL3574508 | 0.84 | ABCG2 (0.59) | ABCG2NFE2L2ALDH1A1KRASHPGD | |
| SCHEMBL6284512 | 0.84 | ABCG2 (0.44) | ABCG2NFE2L2ALDH1A1HDAC3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | claimed |
| CN-110499011-B | Waterproof plastic uptake film and preparation method and application thereof | 宁波咖飞姆新材料有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | claimed |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2017-12-21 | — | — | US | claimed |
| EP-1429768-B1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-11-16 | — | — | EP | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | CA6, CA13, EPCAM | ABCG2 781/4885NFE2L2 370/4885ALDH1A1 137/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | ABCG2 999/4885NFE2L2 4821/4885ALDH1A1 3087/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | ABCG2 749/4885NFE2L2 4343/4885ALDH1A1 2943/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | ABCG2 1946/4885NFE2L2 1266/4885ALDH1A1 1569/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | ABCG2 3845/4885NFE2L2 3435/4885ALDH1A1 1723/4885 |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | CA6, CA13, EPCAM | ABCG2 781/4885NFE2L2 370/4885ALDH1A1 137/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | ABCG2 2067/4885NFE2L2 2587/4885ALDH1A1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.